New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;ABMD;THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 20, 2015
07:29 EDTTHORCanaccord would be buyers of Thoratec following favorable ISHLT
Subscribe for More Information
April 17, 2015
07:58 EDTTHORThoratec to hold an investor and analyst meeting
Subscribe for More Information
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
05:35 EDTTHORThoratec announces positive results from ROADMAP study
Thoratec announced results from the ROADMAP Study, or the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV heart failure patients. Survival in the HeartMate II group was 80% at one year, compared with 64% for medically managed patients on an as-treated basis. At one year of follow-up, 39% of patients within the HeartMate II group met the primary endpoint of survival on the original therapy along with a 75 meter increase in six minute walk test distance, compared with 21% of patients on optimal medical management, representing a statistically significant difference.
April 16, 2015
10:04 EDTTHORHigh option volume stocks
Subscribe for More Information
09:52 EDTTHORThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTTHORBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2015
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
10:03 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information
April 13, 2015
17:13 EDTMDTIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:10 EDTMDTIBM establishes a Watson Health Cloud
Subscribe for More Information
April 11, 2015
14:10 EDTTHORLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use